Yukitaka Ueki - Concepedia

Author

Yukitaka Ueki

Sasebo City General Hospital ORCID

Also Known As

M Hayashi, O Higo, Y UEKI, Y Ueki, Y. Ueki, YUKITAKA UEKI, Yukitaka UEKI, Yukitaka Ueki, Yuriko Ueki

242

Publications

5.8K

Citations

H-Index

119

Concepts

All Affiliations

Sasebo City General Hospital Nagasaki University Nagasaki Medical Center Nagasaki University Hospital University of Occupational and Environmental Health Japan

About

Yukitaka Ueki is an author at Sasebo City General Hospital specializing in medicine, immunology, and autoimmune disease.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	28	65	2.5K
2	Health Sciences	9	9	305
3	Allergy	5	5	125
4	Public Health	4	4	131
5	Engineering	1	1	25

Yukitaka Ueki

130

Publications

5.3K

Citations

H-Index

Page 1

	Year	Citations
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial Désirée van der Heijde, James Cheng‐Chung Wei, Maxime Dougados, The Lancet InflammationRheumatologyRheumatoid DisorderAutoimmune DiseaseSpondyloarthritis	2018	349
Glucose Tolerance, Insulin Secretion, and Insulin Sensitivity in Nonobese and Obese Japanese Subjects Kazunari Matsumoto, Seibei Miyake, Mayumi Yano, Diabetes Care	1997	213
Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial Atul Deodhar, Désirée van der Heijde, Lianne S. Gensler, The Lancet RheumatologySpondyloarthritisRheumatic DiseasesPlacebo-controlled TrialInflammatory Rheumatic Disease	2019	208
Increased nitric oxide levels in patients with rheumatoid arthritis. Yukitaka Ueki, Seibei Miyake, Yuko Tominaga, PubMed	1996	185
Phase III Study of the Efficacy and Safety of Subcutaneous Versus Intravenous Tocilizumab Monotherapy in Patients With Rheumatoid Arthritis Atsushi Ogata, Kazuhide Tanimura, Toyohiko Sugimoto, Arthritis Care & Research	2013	137
Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis Shin‐ya Kawashiri, Atsushi Kawakami, Satoshi Yamasaki, Rheumatology International InflammationRheumatologyRheumatoid DisorderAutoimmune DiseaseImmunology	2009	128
Drug free REmission/low disease activity after cessation of tocilizumab (Actemra) Monotherapy (DREAM) study Norihiro Nishimoto, Koichi Amano, Yasuhiko Hirabayashi, Modern Rheumatology	2013	119
Impact of tocilizumab therapy on antibody response to influenza vaccine in patients with rheumatoid arthritis Shunsuke Mori, Yukitaka Ueki, Naoyuki Hirakata, Annals of the Rheumatic Diseases	2012	111
Pneumococcal polysaccharide vaccination in rheumatoid arthritis patients receiving tocilizumab therapy Shunsuke Mori, Yukitaka Ueki, Yukihiro Akeda, Annals of the Rheumatic Diseases	2013	104
Comparison of serum concentrations of soluble adhesion molecules in diabetic microangiopathy and macroangiopathy Kazunari Matsumoto, Yasunori Sera, Yukitaka Ueki, Diabetic Medicine	2002	94

Page 1